secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001558370-24-001465
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q4 2023 revenue $168.4M, guides 2024 revenue $700-720M
--------------------------------------------------------------------------

- WAKIX net revenue $168.4M in Q4 2023 (+31% YoY); full year $582.0M (+33%).
- GAAP diluted EPS $0.45 vs $0.79 YoY; non-GAAP adjusted EPS $0.73 vs $1.01.
- FDA granted priority review for WAKIX in pediatric narcolepsy; PDUFA June 21, 2024.
- 2024 net product revenue guidance $700-720M, up from ~$582M in 2023.
- Repurchased 3.2M shares for $100M in 2023; $150M remaining authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/0001558370-24-001465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837024001465/hrmy-20240222x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer